Akili is a leading digital medicine company, pioneering the development of cognitive treatments through game-changing technologies. Our approach of developing and commercializing technologies designed to directly target the physiology of the brain has established a new category of medicine—medicine that is validated through clinical trials like a drug or medical device, but experienced like entertainment. In June 2020, EndeavorRx, the first product built on our platform was granted marketing authorization and classified as a Class II medical device by the FDA through FDA’s de novo process. EndeavorRx is indicated for use to improve attention function for children ages 8-12 with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. In addition to EndeavorRx, we have a robust pipeline of development programs that are being evaluated in clinical studies by us or our partners.
Company profile
Ticker
AKLI
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Social Capital Suvretta Holdings Corp. I
SEC CIK
Corporate docs
Subsidiaries
Akili Interactive Labs, Inc. ...
IRS number
981586159
AKLI stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
6 Mar 24
DEFA14A
Additional proxy soliciting materials
6 Mar 24
DEF 14A
Definitive proxy
6 Mar 24
S-8
Registration of securities for employees
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
29 Feb 24
8-K
Japanese Product Now Under Review for Nationwide Marketing Approval
26 Feb 24
PRE 14A
Preliminary proxy
23 Feb 24
8-K
Akili Announces Release Date for Fourth Quarter and Full Year 2023
21 Feb 24
8-K
Departure of Directors or Certain Officers
5 Jan 24
Latest ownership filings
4
Jacqueline Studer
12 Mar 24
4
Walter Edward Martucci II
12 Mar 24
4
Matthew Franklin
12 Mar 24
4
John Spinale
23 Feb 24
3
John Spinale
23 Feb 24
SC 13G/A
Cowen Aaron
13 Feb 24
SC 13G
Neuberger Berman Group LLC
12 Feb 24
SC 13G/A
BAILLIE GIFFORD & CO
29 Jan 24
4
Jacqueline Studer
8 Dec 23
4
Santosh Shanbhag
8 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 74.10 mm | 74.10 mm | 74.10 mm | 74.10 mm | 74.10 mm | 74.10 mm |
Cash burn (monthly) | (no burn) | 1.32 mm | 6.14 mm | 6.38 mm | (no burn) | 1.57 mm |
Cash used (since last report) | n/a | 7.88 mm | 36.61 mm | 38.03 mm | n/a | 9.36 mm |
Cash remaining | n/a | 66.22 mm | 37.49 mm | 36.07 mm | n/a | 64.75 mm |
Runway (months of cash) | n/a | 50.1 | 6.1 | 5.7 | n/a | 41.2 |
Institutional ownership, Q2 2023
83.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 38 |
Opened positions | 5 |
Closed positions | 5 |
Increased positions | 6 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 46.24 bn |
Total shares | 65.93 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
PRTC PureTech Health | 12.53 mm | $0.00 |
SC Master | 11.87 mm | $167.05 mm |
Social Capital | 11.87 mm | $13.18 bn |
Temasek | 11.51 mm | $12.78 bn |
Neuberger Berman | 5.78 mm | $6.41 bn |
Baillie Gifford & Co | 4.67 mm | $5.18 bn |
Suvretta Capital Management | 3.84 mm | $4.26 bn |
Comprehensive Financial Management | 1.06 mm | $1.18 bn |
Alyeska Investment | 672.50 k | $746.48 mm |
Wildcat Capital Management | 545.30 k | $605.28 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Mar 24 | Jacqueline Studer | Common Stock | Payment of exercise | Dispose F | No | No | 0.34 | 1,032 | 350.88 | 415,170 |
10 Mar 24 | Walter Edward Martucci II | Common Stock | Payment of exercise | Dispose F | No | No | 0.34 | 2,599 | 883.66 | 900,620 |
10 Mar 24 | Matthew Franklin | Common Stock | Payment of exercise | Dispose F | No | No | 0.34 | 1,615 | 549.10 | 752,283 |
7 Dec 23 | Jacqueline Studer | Common Stock | Grant | Acquire A | No | No | 0 | 69,750 | 0.00 | 416,202 |
7 Dec 23 | Jacqueline Studer | Stock Option Common Stock | Grant | Acquire A | No | No | 0.4 | 280,500 | 112.20 k | 280,500 |
News
Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
27 Mar 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
27 Mar 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
27 Mar 24
Why MariaDB Shares Are Trading Higher By Around 100%; Here Are 20 Stocks Moving Premarket
27 Mar 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
26 Mar 24
Press releases
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
29 Feb 24
PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in Japan
27 Feb 24
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx® for Pediatric ADHD Patients in Japan
26 Feb 24